Polysaccharide Nanogels for the Delivery of Gemcitabine Hydrochloride

2021 ◽  
Author(s):  
Havva Rezaei Rudmianeh ◽  
Mostafa Shourian ◽  
Reza Ansari ◽  
Fateme Ghanbari Pirbasti ◽  
S Mohsen Asghari
Keyword(s):  
Gemcitabine Hydrochloride

scholarly journals Development and Characterization of Nanoparticles for the Delivery of Gemcitabine Hydrochloride

2014 ◽  
Vol 2014 ◽  
pp. 1-6 ◽  
Author(s):  
Rekha Khaira ◽  
Jyoti Sharma ◽  
Vinay Saini
Keyword(s):  
Metastatic Cancer ◽  
Entrapment Efficiency ◽  
Diffusion Method ◽  
Pancreatic Cell ◽  
Gemcitabine Hydrochloride ◽  
First Choice ◽  
Starting Dose ◽  
Dose Ranging ◽  
Size And Morphology

Gemcitabine (2,2-difluorodeoxycytidine) is a deoxycytidine analog, currently being used as a first-choice drug in pancreatic metastatic cancer. Gemcitabine is administered weekly as 30-minute infusion with starting dose ranging from 800 to 1250 mg/m2. The aim of the present work was to develop starch nanoparticles (NPs) for the delivery of gemcitabine hydrochloride that could reduce its dose related side effects and may prolong its retention time (24 hrs) for the treatment of pancreatic cancer. Nanoparticles were prepared by emulsification diffusion method with slight modifications. Size and morphology of nanoparticles were investigated. Particles were spherical in shape with slightly rough surfaces. Particle size and polydispersity index were 231.4 nm and 1.0, respectively while zeta potential of blank NPs and drug loaded NPs were found to be −11.8 mV and −9.55 mV, respectively. Percent entrapment efficiency of different formulations was around∼54% to 65%.In vitrorelease profile studies showed that around 70%–83% of drug was released from different formulations. Anticancerous cell line studies were also performed in human pancreatic cell lines (MIA-PA-CA-2).

ANALYTICAL METHOD DEVELOPMENT AND VALIDATION STUDIES OF GEMCITABINE NIOSOMES

INDIAN DRUGS ◽  
2021 ◽  
Vol 57 (11) ◽  
pp. 45-51
Author(s):  
Pooja Manjarekar ◽  
Tabassum Khan
Keyword(s):  
Analytical Method ◽  
Validation Studies ◽  
High Performance ◽  
Method Development ◽  
Low Cost ◽  
High Performance Liquid Chromatographic ◽  
Good Resolution ◽  
Mobile Phase Flow Rate ◽  
Gemcitabine Hydrochloride ◽  
Short Run

Gemcitabine hydrochloride niosomes were developed in our laboratory in an effort to improve the efficacy of the drug via development of nanotechnology based delivery system. As a part of this exercise, an analytical method was developed and validated to evaluate the developed formulation for assay and release profile studies. A simple, precise, specific and rapid high performance liquid chromatographic method was developed for determination of gemcitabine hydrochloride in niosomes. The developed method exhibited good resolution, short run time and low cost of analysis. The chromatographic analysis was carried on a Waters® (C18, 250 mm x4.6 mm, 5µ) column using water: acetonitrile (95:5 v/v) as the mobile phase, flow rate of 1.2 ml/min and detection at 268 nm. The robustness of the method was evaluated using design of experiments. The validation studies of the developed method were conducted as per ICH guidelines Q2 (R1). The results indicated that the developed method as specific, accurate, precise, reliable, robust, reproducible, and suitable for the quantitative analysis of gemcitabine hydrochloride in the developed niosomes.

Sign in / Sign up

Export Citation Format

Share Document